alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1801 Sodium tartrate. ( a ) Sodium tartrate (C4H4Na2O6·2H2O, CAS Reg. No. 868-18-8) is the disodium salt of l−(+)−tartaric acid. It occurs as transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacture.
( b ) The ingredient meets the specifications of the Food Chemicals Codex, 3d Ed. (1981), p. 303, which is incorporated by reference. Copies are available from the National Academy Press, 2101 Constitution Ave. NW., Washington, DC 20418, or available for inspection at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .*
( c ) In accordance with § 184.1(b)(1), the ingredient is used in food with no limitation other than current good manufacturing practice. The affirmation of this ingredient as generally recognized as safe (GRAS) as a direct human food ingredient is based upon the following current good manufacturing practice conditions of use: ( 1 ) The ingredient is used as an emulsifier as defined in § 170.3(o)(8) of this chapter and as a pH control agent as defined in § 170.3(o)(23) of this chapter.
( 2 ) The ingredient is used in the following foods at levels not to exceed current good manufacturing practice: cheeses as defined in§ 170.3(n)(5) of this chapter; fats and oils as defined in § 170.3(n)(12) of this chapter; and jams and jellies as defined in § 170.3(n)(28) of this chapter.
( d ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[48 FR 52447, Nov. 18, 1983]
§ 20.113 Voluntary product defect reports. Voluntary reports of defects in products subject to the jurisdiction of the Food and Drug Administration are available for public disclosure: ( a ) If the report is submitted by the manufacturer, after deletion of data and information falling within the exemptions established in § 20.61 for trade secrets and confidential commercial or financial information and in § 20.63 for personal privacy.
( b ) If the report is submitted by any person other than the manufacturer, after deletion of names and other information that would identify the person submitting the report and any data or information falling within the exemption established in § 20.63 for personal privacy.
§ 500.88 Regulatory method. ( a ) The sponsor shall submit for evaluation and validation a regulatory method developed to monitor compliance with FDA's operational definition of no residue.
( b ) The regulatory method must be able to confirm the identity of the marker residue in the target tissue at a minimum concentration corresponding to the Rm. FDA will determine the LOD from the submitted analytical method validation data.
( c ) FDA will publish in the Federal Register the complete regulatory method for ascertaining the marker residue in the target tissue in accordance with the provisions of sections 409(c)(3)(A), 512(d)(1)(I), and 721(b)(5)(B) of the act.
( d ) If the sponsor initially submitted a request for an import tolerance under § 510.205 of this chapter, FDA will make the complete regulatory method for ascertaining the marker residue in the target tissue publicly available pursuant to § 510.207(b) of this chapter.
(Approved by the Office of Management and Budget under control number 0910-0228) [52 FR 49586, Dec. 31, 1987, as amended at 67 FR 78174, Dec. 23, 2002; 86 FR 52410, Sept. 21, 2021]
<PAGE>

                                                                  EXHIBIT 10.9.3


                             THIRD AMENDMENT TO THE

                       REVOLVING LINE OF CREDIT AGREEMENT

This THIRD AMENDMENT ("Amendment") is dated as of January 1, 2002, by and
between WFS FINANCIAL INC, a California corporation ("WFS"), and WESTERN
FINANCIAL BANK, a federally-chartered savings bank (the "Bank"), and amends the
REVOLVING LINE OF CREDIT AGREEMENT ("Agreement") entered into by the parties on
June 15, 1999, pursuant to the transfer of certain assets of the Bank to WFS.

                                    RECITALS

A.    The Agreement is being amended to reflect differing interest spreads.

                                    AGREEMENT

      In consideration of the mutual promises set forth herein, and in reliance
upon the recitals set forth above, the parties agree as follows:

   1.       CERTAIN DEFINITIONS

            The definition of "INTEREST SPREAD" is hereby amended as follows:

            "INTEREST SPREAD" shall mean (1) 125 basis points over one-month
            LIBOR for unsecured borrowings and, (2) 90 basis points over
            one-month LIBOR for secured borrowings. In both cases, the LIBOR
            rate used shall be the rate on the last day of the prior month.

   2.       Except as specifically amended herein, all terms of the Agreement as
            previously amended by First and Second amendments to the Agreement
            shall remain in full force and effect.



Wherefore, the undersigned have executed this Amendment on the date set forth
below to be effective as of the date first set forth above.

WFS FINANCIAL INC                         WESTERN FINANCIAL BANK


______________________________            _______________________________
Thomas A. Wolfe, President and            Lee A. Whatcott,
Chief Operating Officer                   Senior Executive Vice President
                                          and Chief Financial Officer
|  Company Name                          | Jurisdiction of Organization |
|---------------------------------------------|------------------------------|
|                                        |                         |
| Astea FSC                                   | Barbados                     |
| Astea International Australian Pty Ltd.     | Australia                    |
| Astea International Japan, Inc.             | Japan                        |
| Astea Israel Ltd.                           | Israel                       |
| Astea Ltd.                                  | England                      |
| Astea Service and Distribution Systems B.V. | Netherlands                  |
| FC Acquisition Corp.                        | Delaware                     |
| Network Data, Inc.                          | Delaware                     |
| Virtual Service Corp.                       | Pennsylvania                 |
|                                        |                         |
|                                        |                         |

----
# • RCRA REVISION CHECKUST 44 E Permit as a ShieldProvision STATE ANALOG IS: FEDERAL ANALOGOUS MORE BROADFEDERAL RCRA STATE EQUIV- STRIN- ER IN REQUIREMENT CITATION CITATION ALENT GENT SCOPE PART 270 - EPAADMINISTERED PERMIT PROGRAMS: THEHAZARDOUS WASTE PERMIT PROGRAM
SUBPARTA - GENERAL INFORMATION

. EFFECT OF A PERMIT exception of requirements not in permit or under Part 268 270.4(a) 810(8) 

# x 

# •

• December 1, 1987 - Page 6 of 8
§ 507.1 Applicability and status. ( a ) The criteria and definitions in this part apply in determining whether an animal food is: ( 1 ) Adulterated within the meaning of: ( i ) Section 402(a)(3) of the Federal Food, Drug, and Cosmetic Act in that the food has been manufactured under such conditions that it is unfit for food; or
( ii ) Section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act in that the food has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health; and
( 2 ) In violation of section 361 of the Public Health Service Act (42 U.S.C. 264).
( b ) The operation of a facility that manufactures, processes, packs, or holds animal food for sale in the United States if the owner, operator, or agent in charge of such facility is required to comply with, and is not in compliance with, section 418 of the Federal Food, Drug, and Cosmetic Act or subparts C, D, E, or F of this part and § 507.7 is a prohibited act under section 301(uu) of the Federal Food, Drug, and Cosmetic Act.
( c ) Animal food covered by specific current good manufacturing practice regulations also is subject to the requirements of those regulations.
( d ) Except as provided by § 507.12, if a facility is required to comply with subpart B of part 507 and is also required to comply with subpart B of part 117 of this chapter because the facility manufactures, processes, packs, or holds human food and animal food, then the facility may choose to comply with the requirements in subpart B of part 117, instead of subpart B of part 507, as to the manufacturing, processing, packing, and holding of animal food at that facility. If a facility is required to comply with subpart C of part 507 and is also required to comply with subpart C of part 117 of this chapter, then the facility may choose to comply with the requirements in subpart C of part 117 as to the manufacturing, processing, packing, and holding of animal food at the facility, instead of subpart C of part 507, provided the food safety plan also addresses hazards for the animal food, if applicable, that require a preventive control. When applying the requirements of part 117 of this chapter to animal food, the term “food” in part 117 includes animal food.
§ 315.6 Evaluation of safety. ( a ) Factors considered in the safety assessment of a diagnostic radiopharmaceutical include, among others, the following: ( 1 ) The radiation dose;
( 2 ) The pharmacology and toxicology of the radiopharmaceutical, including any radionuclide, carrier, or ligand;
( 3 ) The risks of an incorrect diagnostic determination;
( 4 ) The adverse reaction profile of the drug;
( 5 ) Results of human experience with the radiopharmaceutical for other uses; and
( 6 ) Results of any previous human experience with the carrier or ligand of the radiopharmaceutical when the same chemical entity as the carrier or ligand has been used in a previously studied product.
( b ) The assessment of the adverse reaction profile includes, but is not limited to, an evaluation of the potential of the diagnostic radiopharmaceutical, including the carrier or ligand, to elicit the following: ( 1 ) Allergic or hypersensitivity responses,
( 2 ) Immunologic responses,
( 3 ) Changes in the physiologic or biochemical function of the target and nontarget tissues, and
( 4 ) Clinically detectable signs or symptoms.
( c ) ( 1 ) To establish the safety of a diagnostic radiopharmaceutical, FDA may require, among other information, the following types of data: ( i ) Pharmacology data,
( ii ) Toxicology data,
( iii ) Clinical adverse event data, and
( iv ) Radiation safety assessment.
( 2 ) The amount of new safety data required will depend on the characteristics of the product and available information regarding the safety of the diagnostic radiopharmaceutical, and its carrier or ligand, obtained from other studies and uses. Such information may include, but is not limited to, the dose, route of administration, frequency of use, half-life of the ligand or carrier, half-life of the radionuclide, and results of clinical and preclinical studies. FDA will establish categories of diagnostic radiopharmaceuticals based on defined characteristics relevant to risk and will specify the amount and type of safety data that are appropriate for each category (e.g., required safety data may be limited for diagnostic radiopharmaceuticals with a well established, low-risk profile). Upon reviewing the relevant product characteristics and safety information, FDA will place each diagnostic radiopharmaceutical into the appropriate safety risk category.
( d ) Radiation safety assessment. The radiation safety assessment must establish the radiation dose of a diagnostic radiopharmaceutical by radiation dosimetry evaluations in humans and appropriate animal models. The maximum tolerated dose need not be established.
§ 520.1408 Methylprednisolone. ( a ) *Specifications.* Each tablet contains 1, 2, or 4 milligrams (mg) of methylprednisolone.
( b ) *Sponsors.* See Nos. 054771 and 069043 in § 510.600(c) of this chapter.
( c ) *Conditions of use in dogs and cats* — ( 1 ) *Amount.* 5 to 15 pounds (lbs): 2 mg; 15 to 40 lbs: 2 to 4 mg; 40 to 80 lbs: 4 to 8 mg. Administer total daily dose orally in equally divided doses 6 to 10 hours apart until response is noted or 7 days have elapsed.
( 2 ) *Indications for use.* As an anti-inflammatory agent.
( 3 ) *Limitations.* Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[78 FR 28824, May 20, 2014, as amended at 83 FR 48946, Sept. 28, 2018; 89 FR 14410, Feb. 27, 2024]
NO. 296-82354-2014 

STATE OF TEXAS § IN THE DISTRICT COURT

§

vs. § 296TH JUDICIAL DISTRICT

§

COREY SMITH § COLLIN COUNTY, TEXAS

NOTICE OF APPEAL

TO THE HONORABLE JUDGE OF SAID COURT: 

Now comes Corey Smith, Defendant in the above styled and numbered cause, and gives 

this written notice of appeal to the Court of Appeals of the State of Texas from the judgment of 

conviction and sentence herein rendered against Corey Smith. 

Respectfully submitted, 

Law Office of Curtis Lilly 

2201 Main, Suite 1220 

Dallas, TX 75201 

Tel: (214) 573-7660 

Fax: (214) 573-7661 

By: 

Curtis Lilly 

State Bar No. 24030063 

clilly@clillylaw.com 

Attorney for Corey Smith 

CERTIFICATE OF SERVICE

This is to certify that on April 20, 2016, a true and correct copy of the above and 

foregoing document was served on the District Attorney's Office, Collin County, by hand 

delivery. 

Curtis Lilly 

Filed: 4/20/2016 6:58:16 PM

Yoon Kim

District Clerk

Collin County, Texas

By Christina Joseph Deputy

Envelope ID: 10223970

Filed: 4/20/2016 6:58:16 PM

Yoon Kim

District Clerk

Collin County, Texas

By Christina Joseph Deputy

Envelope ID: 10223970

 FILED IN 5th COURT OF APPEALS DALLAS, TEXAS 4/21/2016 10:52:22 AM LISA MATZ Clerk
Editorial Note on Part 184
Editorial Note: Nomenclature changes to part 184 appear at 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 69 FR 13717, Mar. 24, 2004; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; and 81 FR 49897, July 29, 2016.

§ 184.1698 Rue. ( a ) Rue is the perennial herb of several species of *Ruta* (*Ruta montana* L., *Ruta graveolens* L., *Ruta bracteosa* L., and *Ruta calepensis* L.). The leaves, buds, and stems from the top of the plant are gathered, dried, and then crushed in preparation for use, or left whole.
( b ) The ingredient is used in all categories of food in accordance with § 184.1(b)(2) of this chapter at concentrations not to exceed 2 parts per million.
( c ) Prior sanctions for this ingredient different from the uses established in this section do not exist or have been waived.
[43 FR 3705, Jan. 27, 1978]
Exhibit 31.2  CERTIFICATION  I, Anders A. Suarez, certify that:  1. I have reviewed this annual report on Form 10-K of Amerityre Corporation;  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;  4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:  (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others, particularly during the period in which this report is being prepared; and  (b) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and  (c) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.  5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):  (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and  (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.  Date: September 12, 2007  /s/Anders A. Suarez
Anders A. Suarez
Chief Financial Officer
----

----

| 1. Execution date      | July 7, 2011                                                                                                                                                                                                       |
|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 2. Previous Owners     | Messrs. Giovanni Polonio and Sergio Bianchi and Ms. Angelina Rondanin                                                                                                                                              |
| 3. Current Owner       | Solemax                                                                                                                                                                                                            |
| 4. Portion of the land | Municipality of Canaro (RO), sheet 9, parcels 120 and 122; sheet 10, parcels 18, 19, 21, 53, 55, 56, 57, 116, 154, 156, 157, 160, 161, 163, 165, 167 and 169, size 11.66.78 hectares.                              |
| 5. Duration            | 21 years (until June 30, 2032)                                                                                                                                                                                     |
| 6. Consideration       | As consideration for the 21-year building right, Tecnoenergy paid an amount of Euro 686,676.76. This consideration has been fully paid upon execution and acknowledgement of such payment is included in the deed. |
| 7. Easements           | An electric easement right is in place in favour of Enel on parcel 159.                                                                                                                                            |
| 8. Competent Court     | Exclusive jurisdiction of the court of Rovigo.                                                                                                                                                                     |

----

1 The original language version is on file with the Registrant and is available upon request.

----

----
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-1999
<PERIOD-START>                             JAN-01-1999
<PERIOD-END>                               APR-04-1999
<CASH>                                           4,171
<SECURITIES>                                         0
<RECEIVABLES>                                    1,732
<ALLOWANCES>                                       319
<INVENTORY>                                      7,253
<CURRENT-ASSETS>                                16,015
<PP&E>                                          20,332
<DEPRECIATION>                                   9,045
<TOTAL-ASSETS>                                  28,654
<CURRENT-LIABILITIES>                            7,023
<BONDS>                                          4,573
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                            41
<OTHER-SE>                                      16,699
<TOTAL-LIABILITY-AND-EQUITY>                    28,654
<SALES>                                          8,105
<TOTAL-REVENUES>                                 8,105
<CGS>                                            6,438
<TOTAL-COSTS>                                    6,438
<OTHER-EXPENSES>                                 1,987
<LOSS-PROVISION>                                    20
<INTEREST-EXPENSE>                                  82
<INCOME-PRETAX>                                  (348)
<INCOME-TAX>                                      (65)
<INCOME-CONTINUING>                              (283)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     (283)
<EPS-PRIMARY>                                    (.07)
<EPS-DILUTED>                                    (.07)
        

</TABLE>
#### People of the State of Illinois, Plaintiff-Appellee, v. Andrew Watson, Defendant-Appellant.

Gen. No. 52,725. (Abstract of Opinion.)

First District, Second Division.

May 20, 1969.

Gerald W. Getty, Public Defender of Cook County, of Chicago (James J. Doherty, Assistant Public Defender, of counsel), for appellant;

Edward V. Hanrahan, State’s Attorney of Cook County, of Chicago (Elmer C. Kissane and James B. Haddad, Assistant State’s Attorneys, of counsel), for appellee.

Opinion by

MR. PRESIDING JUSTICE LYONS.

Not to be published in full.
Order entered August 14, 2013

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-12-01470-CV

SAM GRIFFIN FAMILY INVESTMENTS-I, INC. D/B/A 

BUMPER TO BUMBER CAR WASH, Appellant

V.

DALLAS CENTRAL APPRAISAL DISTRICT, Appellee

On Appeal from the 160th Judicial District Court

Dallas County, Texas

Trial Court Cause No. 10-10450-H

ORDER

We GRANT appellant’s August 12, 2013 motion for an extension of time to file a brief. 

Appellant shall file its brief on or before Monday, August 19, 2013.

/s/ DAVID LEWIS 

JUSTICE